Want to see XXII full AI Analyst Report?
22nd Century (XXII) Stock Price & Analysis
XXII Stock Chart & Stats
- Day’s Range
- $0.04 - $0.07
- 52-Week Range
- $0.04 - $447.35
- Previous Close
- $0.07
- Volume
- N/A
- Average Volume (3M)
- 31.88M
- Market Cap
- $1.42M
- Enterprise Value
- -$3.46M
- Total Cash (Recent Filing)
- $6.06M
- Total Debt (Recent Filing)
- $1.30M
- Price to Earnings (P/E)
- 0.0
- Beta
- 2.75
- Next Earnings
- Nov 16, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Revenue And Gross Profit
The latest quarter showed meaningful commercial improvement, with sharply higher revenue and a return to positive gross profit. If sustained, this combination could improve operating leverage, validate demand for low-nicotine products, and support progress toward a more durable earnings model.
Expanding Low-Nicotine Distribution
Broader retail distribution and rising repeat purchases can strengthen brand awareness and create a larger base for recurring product revenue. The company’s proprietary low-nicotine portfolio also positions it in a differentiated category that management describes as largely unserved.
Improved Balance Sheet
Lower leverage and restored positive equity provide a stronger capital structure than the company had previously. This can reduce balance-sheet pressure, preserve strategic flexibility, and give management more capacity to focus on commercial execution even though operating losses remain.
Bears Say
Persistent Cash Burn
The company is not yet self-funding its operations, as both operating and free cash flow remain materially negative. Continued cash burn can constrain investment in product expansion, increase dependence on external financing, and raise execution risk if profitability takes longer to achieve.
Negative Margins And Ongoing Losses
Revenue growth has not yet translated into sustainable profitability: gross profit and operating profitability remain negative, while the company continues to report a net loss. Persistent margin weakness limits internally generated capital and leaves the long-term business model dependent on further improvement.
Equity Dilution Risk
Frequent equity issuance provides financing but dilutes existing shareholders and may remain necessary while cash flow is negative. The enlarged ATM capacity increases potential dilution over the coming months, making per-share value more dependent on successful operating improvement.
22nd Century News
XXII FAQ
What was 22nd Century’s price range in the past 12 months?
What is 22nd Century’s market cap?
When is 22nd Century’s upcoming earnings report date?
How were 22nd Century’s earnings last quarter?
Is 22nd Century overvalued?
Does 22nd Century pay dividends?
What is 22nd Century’s EPS estimate?
How many shares outstanding does 22nd Century have?
What happened to 22nd Century’s price movement after its last earnings report?
Which hedge fund is a major shareholder of 22nd Century?
What is the TipRanks Smart Score and how is it calculated?
Company Description
22nd Century
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
- Sector
- Consumerdefensive
- Industry
- Tobacco
- CEO
- Lawrence D. Firestone
- Employees
- 32
- Website
- www.xxiicentury.com
- Address
- 321 Farmington Road, Mocksville, NY, 27028, US
22nd Century (XXII) Earnings & Revenues
XXII Earnings Call
Earnings Call SentimentNeutral
The call conveyed cautious optimism: management reported clear early commercial progress with sequential revenue growth, gross loss improvement, strategic retail distribution wins, regulatory validation (FDA authorization) and a stable cash position. However, material challenges remain — operating losses and negative adjusted EBITDA widened, profitability is below targets, low-margin contracts persist, and retail adoption is uneven. Management plans focused investments in marketing and distribution with a target of ~5,000 outlets by year-end, but execution risk and competitive headwinds mean near-term results may continue to be pressured.
View all XXII earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 2 | 16 |
| Technical Analysis | 4 | 2 | 4 |
| Moving Averages | 0 | 0 | 12 |







